Twist Bioscience insider plans $279K stock sale

Rule 144 notice details Emily M. Leproust’s planned sale of 1,687 TWST shares and significant prior insider sales in recent months.

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) reported that Emily M. Leproust plans to sell 1,687 shares of common stock through Fidelity Brokerage Services LLC under Rule 144. The planned sale has an aggregate market value of $279,183.99, with 62,707,424 shares outstanding as of the notice.

In the prior three months, Leproust reported multiple Rule 144 sales of Twist Bioscience common stock, including 356,546 shares for $56,330,878.38 on September 17, 2026. The filing notes that the sale includes shares needed to cover a tax obligation from a vested equity award.

Key Figures

Shares to be sold under Rule 144: 1,687 shares Aggregate market value of planned sale: $279,183.99 Shares outstanding: 62,707,424 shares +4 more

7 metrics

Shares to be sold under Rule 144 1,687 shares Planned sale of Twist Bioscience common stock reported for September 21, 2026

Aggregate market value of planned sale $279,183.99 Value of 1,687 shares of Twist Bioscience common stock to be sold under Rule 144

Shares outstanding 62,707,424 shares Number of Twist Bioscience common shares outstanding referenced in the securities information

Largest recent sale by Emily M. Leproust 356,546 shares Sale of Twist Bioscience common stock on September 17, 2026

Proceeds from largest recent sale $56,330,878.38 Value of 356,546 shares of Twist Bioscience common stock sold on September 17, 2026

Another notable recent sale 113,318 shares for $14,183,062.19 Sale of Twist Bioscience common stock on August 10, 2026 by Emily M. Leproust

Date of notice September 21, 2026 Date on which the Rule 144 notice for Twist Bioscience was signed and dated

Key Terms

Rule 144, Restricted Stock Vesting, aggregate market value, vested equity award distribution, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 09/18/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

aggregate market value financial

"1687 | 279183.99 | 62707424 | 09/21/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

vested equity award distribution financial

"resulting from the settlement of a vested equity award distribution."

attorney-in-fact regulatory

"as attorney-in-fact for Emily M. Leproust."

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Rule 144 filing for TWST disclose about planned share sales?

The filing discloses that 1,687 shares of Twist Bioscience common stock are planned to be sold under Rule 144 through Fidelity Brokerage Services LLC, with an aggregate market value of $279,183.99 as of September 21, 2026.

How many Twist Bioscience (TWST) shares are outstanding according to this notice?

The notice states that there are 62,707,424 shares of Twist Bioscience common stock outstanding, as referenced in the securities information section of the Rule 144 form.

What prior sales of TWST shares has Emily M. Leproust reported in the last three months?

Over the past three months, Emily M. Leproust reported several sales of Twist Bioscience common stock, including 356,546 shares for $56,330,878.38 on September 17, 2026 and 113,318 shares for $14,183,062.19 on August 10, 2026.

What is the purpose of part of the TWST shares being sold under this Rule 144 filing?

The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution for Emily M. Leproust.

Who is the broker handling the planned Rule 144 sale of TWST shares?

The planned Rule 144 sale of Twist Bioscience common stock is to be executed through Fidelity Brokerage Services LLC, identified with its address in Smithfield, Rhode Island in the securities information section.

When was the Rule 144 notice for TWST filed and for what security type?

The Rule 144 notice was dated September 21, 2026 and relates to common stock of Twist Bioscience Corp listed on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 04:55 PM Accepted by SEC EDGAR 09/21/2026 - 04:54 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001753655
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Twist Bioscience Corp
SEC File Number	001-38720
Address of Issuer	681 GATEWAY BLVD. SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	800-719-0671
Name of Person for Whose Account the Securities are To Be Sold	Leproust Emily M.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1687	279183.99	62707424	09/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/18/2026	Restricted Stock Vesting	Issuer			1687	09/18/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	06/22/2026	1688	147400.21
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	06/25/2026	18880	1793600.00
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	08/03/2026	5101	435223.44
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	08/10/2026	113318	14183062.19
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	08/12/2026	19952	2495508.37
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	08/21/2026	6639	923261.83
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	08/25/2026	41570	6317760.97
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	09/08/2026	2302	282280.22
Emily M. Leproust 681 Gateway Blvd South San Francisco CA 94080	Common	09/17/2026	356546	56330878.38

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	09/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Emily M. Leproust.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)